The Havana trial, a randomized, prospective study, demonstrated that expert interpretation of genotypic resistance test (GRT) results improved virological outcomes in human immunodeficiency virus type 1 (HIV-1)-infected patients for whom highly active antiretroviral therapy (HAART) was failing. The impact of expert advice in routine clinical practice is unknown. We retrospectively evaluated the virological outcomes of 74 patients for whom HAART was failing and whose clinical providers accepted or rejected HAART regimens recommended by an expert panel who routinely reviewed GRT results. Fifty (68%) of 74 patients received regimens recommended by the expert panel ("advice accepted" [AA]), and 24 patients (32%) received regimens per the clinician's preference ("advice rejected" [AR]). After 24 weeks, AA and AR groups had median decreases in the plasma HIV-1 RNA viral load of 2.6 and 1.3 log 10 copies/mL, respectively ( ). Twenty-six (52%) P p .0001 of 50 patients in the AA group and 5 (21%) of 24 patients in the AR group had a plasma HIV-1 RNA viral load of !50 copies/mL ( ). Consideration should be given to enlisting expert assistance in the inter-P p .01 pretation of GRT results in routine clinical practice.
The benefits of genotypic resistance testing in selecting antiretroviral regimens for HIV-infected patients with virological failure have been demonstrated in randomized, prospective studies [1] [2] [3] . As a result, genotypic resistance tests (GRTs) are recommended in clinical practice to treat patients with acute HIV-1 infection, with chronic HIV-1 infection that failed to respond to у1 antiretroviral regimen, and during pregnancy [4, 5] .
Knowledge of HIV-1 mutations that confer resistance to antiretroviral medications is evolving [4, [6] [7] [8] [9] [10] . Consequently, the interpretation of GRT results has become increasingly complex. The Havana study demonstrated that expert interpretation of resistance assay results can beneficially impact virological outcomes in patients for whom a second HAART regimen is failing [3] . Expert advice in the interpretation of GRT results has also been strongly recommended in the updated 2002 Department of Health and Human Services/Kaiser Family Foundation treatment guidelines [5] .
The impact of genotypic resistance testing and expert advice in routine clinical practice has not been reported in the literature. At our urban public clinic (the CORE Center), an expert panel composed of 3 infectious diseases physicians and 1 clinical pharmacist routinely reviewed genotypic resistance assay results in conjunction with the patient's antiretroviral history. This group provided expert advice regarding choices for subsequent HAART regimens for all patients. In this study, we retrospectively evaluated the virological outcome of patients who underwent GRTs and whose clinical providers accepted or rejected the expert advice-recommended regimens.
METHODS

Study population.
The study population comprised HIV-1-infected patients receiving clinical care at the Downloaded from https://academic.oup.com/cid/article-abstract/37/5/708/312055 by guest on 07 February 2019 CORE Center, an urban public clinic of the Cook County Bureau of Health in Chicago. The CORE Center is the largest public provider of outpatient HIV care in metropolitan Chicago, treating ∼3500 patients infected with HIV-1. Primary medical care is provided by 16 adult infectious diseases attending physicians, 10 infectious diseases fellows, 2 pediatric infectious diseases attending physicians, 10 internists, 3 physicians' assistants, and 6 nurse practitioners. Most medical providers have 13 years experience in outpatient HIV management and provide care to 50-250 patients.
Patients with HIV-1 infection who were experiencing virological failure with HAART were eligible to undergo GRTs if they met guideline criteria established by the CORE Center. These guidelines were established to improve the costeffectiveness of testing in part by screening for nonadherence. For GRTs to be performed, the following conditions had to be met: (1) the patient must be taking and experiencing treatment failure with a у3-drug HAART regimen; (2) the patient must have a viral load of 12000 copies/mL by branched DNA, as was recommended by the genotypic reference laboratory at the time of the study for reliable amplification of HIV-1; and (3) the patient must be adequately adherent to the current treatment regimen and clinic visits, as judged by an interview with the primary provider and a clinical pharmacist. Clinicians were required to list the patient's antiretroviral history and prior adverse reactions to antiretroviral medications on the requisition form.
All GRT results were reviewed weekly by the expert panel. Recommendations were made before clinicians received the GRT results. Expert advice recommendations proposed by the panel were based on the following factors: (1) interpretation of resistance mutations present, on the basis of published data [4, [6] [7] [8] [9] [10] ; (2) consideration of potential cross-resistance between agents; (3) knowledge of any allergies or adverse reactions to antiretrovirals, as reported by the clinician on the requisition form; and (4) the patient's antiretroviral history. Clinical providers were free to accept or reject expert advice and choose alternative HAART regimens. The acceptance of expert advicerecommended regimens was determined by retrospective chart review.
Study design and definitions. Patients у18 years of age who underwent GRTs and had a baseline CD4 cell count and plasma HIV-1 RNA viral load measured during the period of 1 November 2000 through 1 November 2001 were eligible for the study; patients were excluded from the analysis if pregnancy was documented in the medical chart or if they were nonadherent to therapy, missed follow-up clinic visits, or had no blood samples obtained at 24 weeks. Nonadherence to medications was defined by documentation in the medical chart by the medical provider upon chart review.
Patients who met inclusion criteria were divided into 2 The primary end points were the changes in log 10 HIV-1 RNA viral load and CD4 cell count at 24 weeks and the proportion of patients with a plasma HIV-1 RNA viral load of !50 copies/mL in the AA and AR groups.
Plasma HIV-1 RNA viral load, CD4 cell count, and GRTs. All plasma HIV-1 RNA viral load measurements were made at the Cook County Hospital (Chicago, IL) laboratory using the automated branched-chain DNA method (Chiron), with a lower limit of detection of 50 copies/mL. All CD4 cell count measurements were made at the same laboratory using methodology that conformed to Centers for Disease Control and Prevention standards for quality assurance for fluorescenceactivated cell-sorting analyzers throughout the study period.
Sequencing of the reverse-transcriptase and protease genes was performed on plasma viral RNA at baseline by Quest Diagnostics (Nichols Institute; San Juan Capistrano, CA), in accordance with the instructions of the manufacturer. Detection of primary and secondary reverse-transcriptase and protease resistance mutations was reported to the CORE Center.
Antiretroviral treatments. During the study, there were 6 nucleoside reverse-transcriptase inhibitors (NRTIs; zidovudine, lamivudine, didanosine, stavudine, abacavir, and tenofovir), 2 nonnucleoside reverse-transcriptase inhibitors (NNRTIs; nevirapine and efavirenz), and 6 protease inhibitors (PIs; ritonavir, saquinavir, nelfinavir, indinavir, amprenavir, and lopinavirritonavir) available for routine use.
Statistical analysis. Differences in patient characteristics between the AA and AR groups were determined using t tests for continuous variables and a x 2 test of independence for categorical variables. When the assumptions of the t test were not satisfied, a nonparametric Wilcoxon 2-sample test was applied. The plasma HIV-1 RNA viral loads were log 10 -transformed before analysis. A value of 49 copies/mL was implemented for values that were less than the level of detection for the assay (50 copies/mL). AR subgroups were compared in a 1-way analysis of variance, and the Bonferonni t test for antiretroviral use between the AA and AR groups. Overall, 64% and 93% of patients had prior exposure to an NNRTI and PI, respectively. The proportion of patients for whom the first, second, or third or greater HAART regimen had failed was also similar between the 2 groups.
The frequencies of primary reverse-transcriptase and protease mutations identified by GRTs are summarized in table 2. There was no significant difference in the mean number of primary reverse-transcriptase and protease mutations between the 2 groups. Overall, 99% of patients had evidence of у1 primary reverse-transcriptase mutation, 50% had у1 primary nonnucleoside reverse-transcriptase mutation, and 81% had у1 primary protease mutation. Mutations on the reversetranscriptase gene at position K70R (28% vs. 8.3%; ) P p .02 and Y181C/I (26%. vs 4%;
) were statistically more P p .04 prevalent at baseline in the AA group than in the AR group, respectively.
Twenty-four-week virological and immunological response. The virological response to antiretroviral therapy was significantly greater for patients in the AA group than for those in the AR group (table 3) . At 24 weeks, the overall median log decrease in the viral load for all patients was 2.6 log 10 copies/mL for patients in the AA group and 1.3 log 10 copies/mL for patients in the AR group ( ). When data were stratified on the basis of the P p .0001 number of previous HAART regimens, a significant stratum effect was observed. Only patients in the AA group for whom a second HAART regimen was failing had a significantly better virological response than did patients in the AR group (median decrease in plasma HIV-1 RNA viral load, 2.7 vs. 0.6 log 10 copies/mL; ). Patients in the AA group for whom у3 regimens had P p .007 failed had a good virological response to HAART, compared with patients in the AR group; this finding approached statistical significance (median decrease in plasma HIV-1 RNA viral load, 2.5 vs. 0.3 log 10 copies/mL;
). The virological response in P p .06 patients in the AR group also correlated with the number of active drugs recommended by the expert panel. The AR 0 , AR 1 , and AR 2 subgroups had mean decreases in the viral load (‫ע‬SD) of , , and , respectively. A 0.13 ‫ע‬ 0.25 0.64 ‫ע‬ 0.91 1.74 ‫ע‬ 1.1 plasma HIV-1 RNA viral load of !50 copies/mL at 24 weeks was present in 52% of patients in the AA group and 21% of patients in the AR group ( ). P p .01
Patients in the AA and AR groups experienced modest increases in the CD4 cell count without a significant difference between the 2 groups. At 24 weeks, the change in the CD4 cell count was cells/L for patients in the AA group and 6 90 ϫ 10 cells/L for patients in the AR group ( ). 6 43 ϫ 10 P p .06 In a multivariate analysis adjusting for expert advice, HAART failure group, baseline plasma HIV-1 RNA viral load, and receipt of salvage regimens containing lopinavir-ritonavir, acceptance of expert advice was an independent predictor of a plasma HIV-1 RNA viral load of !50 copies/mL at 24 weeks (OR, 4.12; 95% CI, 1.33-12.75).
Reasons for not accepting expert advice. Reasons for not accepting expert advice from the panel were documented in 9 of 24 medical charts of patients in the AR group. A simpler HAART regimen with fewer side effects, high cholesterol level, and enrollment in a clinical trial were reported in 6, 2, and 1 medical charts, respectively. Clinical providers who did not follow expert advice included 13 infectious diseases attendings, 5 internists, 2 infectious diseases fellows, and 3 nurse practitioners.
DISCUSSION
We found that patients who received HAART regimens based on expert advice and GRT results had a significantly better virological outcomes (percentage of patients with plasma HIV-1 RNA viral load !50 copies/mL and decrease in plasma HIV-1 RNA viral load from the baseline value) at 6 months than patients who did not receive expert advice-recommended antiretroviral regimens.
The findings from this retrospective review of clinical practice are comparable to results from previous randomized trials evaluating the impact of expert advice and GRT data on virological outcome [1] [2] [3] . The direct benefit of expert advice in the interpretation of GRT results is difficult to determine in some trials in which GRT results and expert advice were compared with the standard of care [1, 2] . However, the Havana study independently distinguished the added benefit of expert advice in the interpretation of GRT results. As in our study, researchers found an improved virological response in the subset of patients for whom a second HAART regimen was failing [3] .
Our study has several distinguishing characteristics compared with other published studies. The majority of patients had NNRTI and PI exposure before undergoing GRTs [1] [2] [3] . In addition, patients in this study had a greater rate of reversetranscriptase and protease resistance mutations at baseline. Despite these obstacles, our patients, particularly patients in the AA group, had a surprisingly good virological response to HAART at 24 weeks; regardless of HAART regimen failure, each stratum in the AA group had a 12-log decrease in the HIV-1 RNA viral load. In contrast to prior studies in which the virological advantage of GRTs was lost over time, the durability of viral suppression was also greater in a slight majority of patients in the AA group.
A noteworthy feature of this study was the stratum effect on viral load reduction between the AA and AR groups. As in the Havana trial, only patients for whom a second HAART regimen was failing had a significantly better virological response. One may speculate that patients for whom the first regimen is failing have acquired fewer resistance mutations, allowing for a good virological response to changes in HAART, with or without following expert advice recommendations; likewise, it can be hypothesized that patients for whom у3 HAART regimens fail have accumulated more resistance mutations that impede a good virological response, regardless of whether expert interpretation of GRT results was followed.
As seen in previous published studies, the increase in CD4 cell count after HAART regimens were changed did not differ between the 2 groups, despite the greater virological response in the AA group [9] . It is possible that 24 weeks may not be sufficient time to observe a difference in CD4 cell response. Conversely, this finding also suggests that there are immunological benefits with HAART, even in the absence of complete viral suppression [11] .
The results of this study should be interpreted in light of its limitations. This was a nonrandomized, retrospective study with a relatively small number of patients. In addition, the reasons for rejecting expert advice could only be determined by chart review for 9 patients in the AR group. Other factors, such as past drug toxicity, psychosocial issues, patient apprehension regarding drug toxicities or pill burden of HAART regimens, or provider attitude towards the utility of GRTs and expert advice, could not be determined. These variables con-stitute some of the unmeasured differences between the AA and AR groups that may have influenced the outcomes. Additional prospective, observational, clinic-based studies are needed to take into account these variables. Finally, the longterm durability of viral suppression in patients whose HAART regimens are based on GRT findings and expert advice remains to be demonstrated. Despite these limitations, we felt the need to present data reflecting the impact of expert advice on GRT results in a large, urban clinical practice in a setting outside of clinical trials.
In summary, we found that virological outcome is improved when HAART regimens are changed on the basis expert interpretation of GRT results, especially in patients for whom a second regimen is failing. Because cross-resistance between drugs is evident, and because the number of antiretroviral agents available for the treatment of HIV-1 infection is limited, changes in antiretroviral therapy may be better aided by expert interpretation of GRT results. Medical providers who care for HIV-infected patients should consider creating groups who are familiar with resistance mutations to review GRT data in clinical practice.
